267 related articles for article (PubMed ID: 33515082)
21. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
22. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.
Steenholdt C; Palarasah Y; Bendtzen K; Teisner A; Brynskov J; Teisner B; Nielsen CH
Aliment Pharmacol Ther; 2013 Jun; 37(12):1172-83. PubMed ID: 23650912
[TBL] [Abstract][Full Text] [Related]
23. Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.
Otake H; Matsumoto S; Mashima H
Medicine (Baltimore); 2017 Apr; 96(16):e6635. PubMed ID: 28422861
[TBL] [Abstract][Full Text] [Related]
24. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
Weisshof R; Ungar B; Blatt A; Dahan A; Pressman S; Waterman M; Kopylov U; Ben-Horin S; Chowers Y
Inflamm Bowel Dis; 2016 Jul; 22(7):1655-61. PubMed ID: 27120567
[TBL] [Abstract][Full Text] [Related]
25. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
26. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.
Calafat M; Mañosa M; Ricart E; Nos P; Iglesias-Flores E; Vera I; López-Sanromán A; Guardiola J; Taxonera C; Mínguez M; Martín-Arranz MD; de Castro L; de Francisco R; Rivero M; Garcia-Planella E; Calvet X; García-López S; Márquez L; Gomollón F; Barrio J; Esteve M; Muñoz F; Gisbert JP; Gutiérrez A; Hinojosa J; Argüelles-Arias F; Busquets D; Bujanda L; Pérez-Calle JL; Sicilia B; Merino O; Martínez P; Bermejo F; Lorente R; Barreiro-de Acosta M; Rodríguez C; Fe García-Sepulcre M; Monfort D; Cañete F; Domènech E;
J Crohns Colitis; 2022 Jul; 16(6):946-953. PubMed ID: 34864947
[TBL] [Abstract][Full Text] [Related]
27. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.
Cheng J; Hamilton Z; Smyth M; Barker C; Israel D; Jacobson K
Inflamm Bowel Dis; 2017 Oct; 23(10):1762-1773. PubMed ID: 28837517
[TBL] [Abstract][Full Text] [Related]
28. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
[TBL] [Abstract][Full Text] [Related]
29. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
30. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
31. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
Grinman AB; de Souza MDGC; Bouskela E; Carvalho ATP; de Souza HSP
Medicine (Baltimore); 2020 Mar; 99(10):e19359. PubMed ID: 32150077
[TBL] [Abstract][Full Text] [Related]
32. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
[TBL] [Abstract][Full Text] [Related]
33. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
Nanda KS; Cheifetz AS; Moss AC
Am J Gastroenterol; 2013 Jan; 108(1):40-7; quiz 48. PubMed ID: 23147525
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
35. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
[No Abstract] [Full Text] [Related]
36. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
37. Safety and Durability of Accelerated Infliximab Dosing Strategies in Pediatric IBD: A Single Center, Retrospective Study.
Gibson M; Subedi S; Barker DH; Masur S; Mallette MM; Lingannan A; Recinos Soto AA; Esharif D; Maxwell SH; Riaz MS; Herzlinger MI; Shalon LB; Cerezo CS; Kasper VL; Ross AM; Leleiko NS; Shapiro JM
J Pediatr Gastroenterol Nutr; 2023 Aug; 77(2):207-213. PubMed ID: 37084343
[TBL] [Abstract][Full Text] [Related]
38. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.
Zelinkova Z; Bultman E; Vogelaar L; Bouziane C; Kuipers EJ; van der Woude CJ
World J Gastroenterol; 2012 Dec; 18(47):6967-73. PubMed ID: 23322995
[TBL] [Abstract][Full Text] [Related]
39. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
[TBL] [Abstract][Full Text] [Related]
40. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
